MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319599 | Name: Solabegron HCl
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Solabegron, also known as GW-427,353, is a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome. It has been shown to produce visceral analgesia by releasing somatostatin from adipocytes. Solabegron decreases excitability of human enteric neurons via release of somatostatin. Solabegron evokes bladder relaxation and increases micturition reflex threshold in the dog.

Chemical Structure

Solabegron HCl
Solabegron HCl
CAS#451470-34-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 319599

Name: Solabegron HCl

CAS#: 451470-34-1 (HCl)

Chemical Formula: C23H24Cl2N2O3

Exact Mass: 446.1164

Molecular Weight: 447.36

Elemental Analysis: C, 61.75; H, 5.41; Cl, 15.85; N, 6.26; O, 10.73

Price and Availability

Size Price Availability Quantity
1mg USD 450.00 2 Weeks
10mg USD 1,500.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
252920-94-8 (free base)
Synonym
GW-427353; GW 427353; GW427353; GW-427,353; GW 427,353; GW427,353; Solabegron; Solabegron HC1; Solabegron hydrochloride.
IUPAC/Chemical Name
(R)-3'-((2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-carboxylic acid hydrochloride
InChi Key
PMXCGBVBIRYFPR-FTBISJDPSA-N
InChi Code
InChI=1S/C23H23ClN2O3.ClH/c24-20-8-2-6-18(13-20)22(27)15-25-10-11-26-21-9-3-5-17(14-21)16-4-1-7-19(12-16)23(28)29;/h1-9,12-14,22,25-27H,10-11,15H2,(H,28,29);1H/t22-;/m0./s1
SMILES Code
O=C(C1=CC(C2=CC=CC(NCCNC[C@@H](C3=CC=CC(Cl)=C3)O)=C2)=CC=C1)O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 447.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mozaffari S, Nikfar S, Abdollahi M. Drugs of the future for diarrhea- predominant irritable bowel syndrome: an overview of current investigational drugs. Expert Opin Investig Drugs. 2024 Mar;33(3):219-228. doi: 10.1080/13543784.2024.2320703. Epub 2024 Feb 23. PMID: 38366822. 2: Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T. Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density. PLoS One. 2023 Sep 1;18(9):e0290685. doi: 10.1371/journal.pone.0290685. PMID: 37656760; PMCID: PMC10473532. 3: Joseph S, Maria SA, Peedicayil J. Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review. Curr Ther Res Clin Exp. 2022 Apr 6;96:100669. doi: 10.1016/j.curtheres.2022.100669. PMID: 35494662; PMCID: PMC9052038. 4: Nureki I, Kobayashi K, Tanaka T, Demura K, Inoue A, Shihoya W, Nureki O. Cryo-EM structures of the β3 adrenergic receptor bound to solabegron and isoproterenol. Biochem Biophys Res Commun. 2022 Jun 30;611:158-164. doi: 10.1016/j.bbrc.2022.04.065. Epub 2022 Apr 19. PMID: 35489202. 5: Okeke K, Michel-Reher MB, Gravas S, Michel MC. Desensitization of cAMP Accumulation via Human β3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists. Front Pharmacol. 2019 Jun 7;10:596. doi: 10.3389/fphar.2019.00596. PMID: 31263412; PMCID: PMC6590479. 6: Thiagamoorthy G, Cardozo L, Robinson D. Current and future pharmacotherapy for treating overactive bladder. Expert Opin Pharmacother. 2016 Jul;17(10):1317-25. doi: 10.1080/14656566.2016.1186645. Epub 2016 Jun 2. PMID: 27253972. 7: Michel MC, Gravas S. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies. Expert Opin Drug Saf. 2016 May;15(5):647-57. doi: 10.1517/14740338.2016.1160055. Epub 2016 Mar 21. PMID: 26954275. 8: Olivera CK, Meriwether K, El-Nashar S, Grimes CL, Chen CC, Orejuela F, Antosh D, Gleason J, Kim-Fine S, Wheeler T, McFadden B, Balk EM, Murphy M; Systematic Review Group for the Society of Gynecological Surgeons. Nonantimuscarinic treatment for overactive bladder: a systematic review. Am J Obstet Gynecol. 2016 Jul;215(1):34-57. doi: 10.1016/j.ajog.2016.01.156. Epub 2016 Feb 4. PMID: 26851599. 9: Michel MC, Korstanje C. β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. Pharmacol Ther. 2016 Mar;159:66-82. doi: 10.1016/j.pharmthera.2016.01.007. Epub 2016 Jan 22. PMID: 26808167. 10: Burden H, Abrams P. Urinary incontinence in men: current and developing therapy options. Expert Opin Pharmacother. 2016;17(5):715-26. doi: 10.1517/14656566.2016.1145662. Epub 2016 Mar 3. PMID: 26800277. 11: Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. Eur Urol. 2016 Feb;69(2):311-23. doi: 10.1016/j.eururo.2015.09.007. Epub 2015 Sep 28. PMID: 26422675. 12: Thiagamoorthy G, Giarenis I, Cardozo L. Early investigational β3 adreno- receptor agonists for the management of the overactive bladder syndrome. Expert Opin Investig Drugs. 2015;24(10):1299-306. doi: 10.1517/13543784.2015.1076390. Epub 2015 Aug 14. PMID: 26292923. 13: Hertzberg R, Monreal Santiago G, Moberg C. Synthesis of the β3-adrenergic receptor agonist solabegron and analogous N-(2-ethylamino)-β-amino alcohols from O-acylated cyanohydrins - expanding the scope of minor enantiomer recycling. J Org Chem. 2015 Mar 6;80(5):2937-41. doi: 10.1021/acs.joc.5b00322. Epub 2015 Feb 24. PMID: 25689345. 14: Ellsworth P, Fantasia J. Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder. Expert Opin Investig Drugs. 2015 Mar;24(3):413-9. doi: 10.1517/13543784.2015.1001836. Epub 2015 Jan 5. PMID: 25557359. 15: Andersson KE, Martin N, Nitti V. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013 Oct;190(4):1173-80. doi: 10.1016/j.juro.2013.02.104. Epub 2013 Feb 28. PMID: 23458471. 16: Igawa Y, Michel MC. Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):177-83. doi: 10.1007/s00210-012-0824-1. Epub 2012 Dec 21. PMID: 23263450. 17: Chapple CR. β3-agonist therapy: a new advance in the management of overactive bladder? Eur Urol. 2012 Nov;62(5):841-2. doi: 10.1016/j.eururo.2012.08.006. Epub 2012 Aug 13. PMID: 22901985. 18: Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012 Nov;62(5):834-40. doi: 10.1016/j.eururo.2012.05.053. Epub 2012 Jun 5. PMID: 22695239. 19: Ellsworth P. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies. Postgrad Med. 2012 May;124(3):16-27. doi: 10.3810/pgm.2012.05.2544. PMID: 22691895. 20: Tasler S, Baumgartner R, Behr-Roussel D, Oger-Roussel S, Gorny D, Giuliano F, Ney P. An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant. Eur J Pharm Sci. 2012 Aug 15;46(5):381-7. doi: 10.1016/j.ejps.2012.03.001. Epub 2012 Mar 10. PMID: 22430195.

View History

PLX-647

PLX-647

Featured